Quintet Private Bank Europe S.A. Reduces Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Quintet Private Bank Europe S.A. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 22.2% in the 4th quarter, HoldingsChannel reports. The firm owned 32,790 shares of the company’s stock after selling 9,337 shares during the quarter. Quintet Private Bank Europe S.A.’s holdings in Johnson & Johnson were worth $4,742,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in JNJ. Wealth Group Ltd. purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at approximately $213,000. Swedbank AB increased its holdings in Johnson & Johnson by 5.3% in the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after buying an additional 111,570 shares in the last quarter. Donaldson Capital Management LLC raised its position in shares of Johnson & Johnson by 2.1% in the third quarter. Donaldson Capital Management LLC now owns 343,944 shares of the company’s stock worth $55,740,000 after acquiring an additional 7,092 shares during the period. Cortland Associates Inc. MO grew its position in shares of Johnson & Johnson by 21.2% during the 3rd quarter. Cortland Associates Inc. MO now owns 2,008 shares of the company’s stock valued at $325,000 after acquiring an additional 351 shares during the period. Finally, Intact Investment Management Inc. increased its stake in shares of Johnson & Johnson by 23.3% in the 3rd quarter. Intact Investment Management Inc. now owns 91,809 shares of the company’s stock valued at $14,879,000 after purchasing an additional 17,320 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on JNJ shares. Morgan Stanley dropped their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Raymond James dropped their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Barclays increased their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Bank of America cut their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Stock Down 1.1 %

NYSE JNJ opened at $165.48 on Wednesday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The business’s fifty day simple moving average is $151.73 and its 200-day simple moving average is $156.12. The firm has a market cap of $398.41 billion, a PE ratio of 24.88, a P/E/G ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the business posted $2.29 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.00%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.